Almost all antipsychotics result in weight gain: a meta-analysis.

Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. Plos One. 2014;9(4):e94112. DOI: 10.1371/journal.pone.0094112. PubMed PMID: 24763306; PubMed Central PMCID: PMC3998960.

Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries.

Laursen TM, Wahlbeck K, Hällgren J, Westman J, Ösby U, Alinaghizadeh H, et al.. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. Plos One. 2013;8(6):e67133. DOI: 10.1371/journal.pone.0067133. PubMed PMID: 23826212; PubMed Central PMCID: PMC3691116.

Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis.

Pearsall R, Smith DJ, Pelosi A, Geddes J. Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis. Bmc Psychiatrybmc Psychiatry. 2014;14:117. DOI: 10.1186/1471-244X-14-117. PubMed PMID: 24751159; PubMed Central PMCID: PMC4018503.

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.

Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology. 2003;28(3):527-9. DOI: 10.1038/sj.npp.1300089. PubMed PMID: 12629532.

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. AJP. 2005;162(5):954-62. DOI: 10.1176/appi.ajp.162.5.954. PubMed PMID: 15863798.

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.

Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Res. 2006;82(1):115-7. DOI: 10.1016/j.schres.2005.10.001. PubMed PMID: 16326074.

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology. 2007;192(3):441-8. DOI: 10.1007/s00213-007-0731-1. PubMed PMID: 17310385.

Interventions to reduce weight gain in schizophrenia.

Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007;(1):CD005148. DOI: 10.1002/14651858.CD005148.pub2. PubMed PMID: 17253540.

Schizophrenia, the metabolic syndrome and diabetes.

Holt RIG, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med. 2004;21(6):515-23. DOI: 10.1111/j.1464-5491.2004.01199.x. PubMed PMID: 15154933.

Differential metabolic effects of antipsychotic treatments.

Haupt DW. Differential metabolic effects of antipsychotic treatments. European Neuropsychopharmacol. 2006;16 Suppl 3:S149-55. DOI: 10.1016/j.euroneuro.2006.06.003. PubMed PMID: 16872808.